SCHEMBL25974459

SCHEMBL25974459

COCCOc1cc(Cl)cc(F)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.46
KDR P35968 7/20 0.41
FLT1 P17948 6/20 0.41
FGFR1 P11362 5/20 0.40
EGFR P00533 4/20 0.39
FLT4 P35916 2/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
S1PR4 O95977 1/20 0.37
HTR2C P28335 2/20 0.36
HTR2B P41595 1/20 0.36
RET P07949 1/20 0.36
KIF5B P33176 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25974441 0.82 RET (0.34) PLAUKDRFLT1FGFR1EGFR
SCHEMBL25958932 0.77 ERN1 (0.39) KDRFLT1FGFR1EGFRFLT4
SCHEMBL16546179 0.72 S1PR4 (0.34) MAPTS1PR4SMN1; SMN2MEN1ALDH1A1
SCHEMBL8256480 0.72 SYK (0.38) KDRFLT1FGFR1RETKIF5B
SCHEMBL23239912 0.71 L3MBTL1 (0.47) PLAUL3MBTL1POLBMAPTTDP1
SCHEMBL14039976 0.71 HTR2C (0.47) PLAUKDRFLT1L3MBTL1POLB
SCHEMBL13696458 0.71 L3MBTL1 (0.47) EGFRL3MBTL1MAPTTDP1SMN1; SMN2
SCHEMBL8251583 0.71 L3MBTL1 (0.47) L3MBTL1POLBMAPTTDP1SMN1; SMN2
SCHEMBL14345658 0.71 HTR2C (0.52) PLAUKDRFLT1FGFR1L3MBTL1
SCHEMBL10144167 0.70 TSHR (0.41) SMN1; SMN2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed